Article View: be.science
Article #455Cancer - Press Review (January 12, 2013) – Revue de presse (12 janvier 2013)
From: SMW
Date: Sat, 12 Jan 2013 12:59
Date: Sat, 12 Jan 2013 12:59
204 lines
9997 bytes
9997 bytes
Cancer – Press Review – Revue de Presse Every week on http://marclacroixcancerblog.blogspot.com Chaque semaine sur http://marclacroixcancerblog.blogspot.com Press Review (January 12, 2013) – Revue de presse (12 janvier 2013) Pap Test Could Help Find Cancers of Uterus and Ovaries The Pap test, which has prevented countless deaths from cervical cancer, may eventually help to detect cancers of the uterus and ovaries as well, a new study suggests By Denise Grady. In New York Times http://www.nytimes.com/2013/01/10/health/pap-test-may-prove-useful-at-detecting-more-types-of-cancer-study-suggests.html?_r=0 Sickle Cells Show Potential to Attack Aggressive Cancer Tumors By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed a way to deploy the misshapen red blood cells to fight cancer tumors. In Science Daily (press release) http://www.sciencedaily.com/releases/2013/01/130109185852.htm High Fiber Diet Prevents Prostate Cancer Progression, Study Shows A high-fiber diet may have the clinical potential to control the progression of prostate cancer in patients diagnosed in early stages of the disease. In Science Daily (press release) http://www.sciencedaily.com/releases/2013/01/130109162032.htm Scientists Use Pap Test Fluid to Detect Ovarian, Endometrial Cancers Using cervical fluid obtained during routine Pap tests, scientists at the Johns Hopkins Kimmel Cancer Center have developed a test to detect ovarian and endometrial cancers. In a pilot study, the "PapGene" test, which relies on genomic sequencing of cancer-specific mutations, accurately detected all 24 (100 percent) endometrial cancers and nine of 22 (41 percent) ovarian cancers. In Science Daily (press release) http://www.sciencedaily.com/releases/2013/01/130109151122.htm Two-Drug Combination May Slow Deadly Thyroid Cancer A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic- led study published in the journal Science Translational Medicine. The two drugs together resulted in greater anti-cancer activity in ATC than either drug alone, says lead researcher Keith Bible, M.D., Ph.D., a Mayo Clinic oncologist. In Science Daily (press release) http://www.sciencedaily.com/releases/2013/01/130108162238.htm Ovarian cancer stem cell study puts targeted therapies within reach Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study, which paves the way for developing novel targeted ovarian cancer therapies, is published online in the current issue of Cell Cycle. Lead author Yingqun Huang, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences, and her colleagues have demonstrated a connection between two concepts that are revolutionizing the way cancer is treated. In Eureka! Science News http://esciencenews.com/articles/2013/01/09/ovarian.cancer.stem.cell.study.puts.targeted.therapies.within.reach Microscopic Blood in Urine Unreliable Indicator of Urinary Tract Cancer Microscopic amounts of blood in urine have been considered a risk factor for urinary tract malignant tumors. However, only a small proportion of patients referred for investigation are subsequently found to have cancer. A new Kaiser Permanente Southern California study published in the February Mayo Clinic Proceedings reports on the development and testing of a Hematuria Risk Index to predict cancer risk. This could potentially lead to significant reductions in the number of unnecessary evaluations. In Science Daily (press release) http://www.sciencedaily.com/releases/2013/01/130109151206.htm Brief Life Expectancy Should Rule Out Certain Cancer Screenings: Study Risks outweigh benefits for those with few years left, researchers say. In U.S. News & World Report http://health.usnews.com/health-news/news/articles/2013/01/09/brief-life-expectancy-should-rule-out-certain-cancer-screenings-study Oil Sands Raise Levels of Cancer-Causing Compounds in Regional Waters From carcinogens to acid rain, tar sands development is raising levels of industrial pollution across the north. By David Biello. In Scientific American http://www.scientificamerican.com/article.cfm?id=oil-sands-raise-levels-of-carcinogens-in-regional-waters ASCO Blueprint to Improve Cancer Survivor Care The American Society of Clinical Oncology (ASCO) has issued recommendations to keep cancer survivors from falling "through the cracks." Those words, from ASCO president Sandra Swain, MD, refer to the health risks that imperil survivors as they transition out of treatment and the related need for planned and coordinated ongoing care to catch and mitigate those risks. By Nick Mulcahy. In Medscape http://www.medscape.com/viewarticle/777278 US Cancer Death Rates Continue to Fall: Report Deaths from cancer continue to drop for American men and women from most racial and ethnic groups, according to a new report, with significant declines seen for lung, colorectal, breast, prostate and other forms of cancer. By Steven Reinberg. In Health.com http://news.health.com/2013/01/08/u-s-cancer-death-rates-continue-to-fall-report/ Source: http://www.cancer.gov/ncicancerbulletin/010813/page5 Cancer du sein : la mastectomie chimique à l'essai Susan Love et coll., qui publient dans « Cancer Prevention Research » les résultats de leurs travaux de phase I, parlent de « mastectomie chimique ». Il s’agit ni plus ni moins de l’administration d’une chimiothérapie par le mamelon. Par Emmanuel de Viel. Dans Le Quotidien du Médecin http://www.lequotidiendumedecin.fr/specialites/cancerologie/cancer-du-sein-la-mastectomie-chimique-l-essai La protéine de la maladie de Huntington impliquée dans le cancer du sein. On l’ignorait jusque-là , la protéine huntingtine mutée, qui est connue pour être responsable de la maladie de Huntigton, est exprimée dans le tissu mammaire sain ainsi que dans les tumeurs mammaires. Par Béatrice Vuaille. Dans Le Quotidien du Médecin http://www.lequotidiendumedecin.fr/specialites/cancerologie/la-proteine-de-la-maladie-de-huntington-impliquee-dans-le-cancer-du-sein Les bêtabloquants, nouvelle piste contre le cancer du poumon NPC ? Les patients atteints de cancer bronchique non à petites cellules (CBNPC) qui reçoivent des bêtabloquants pour une hypertension ou une cardiopathie en plus d'une radiothérapie voient leur survie globale prolongée de façon significative par rapport à ceux qui n'en reçoivent pas, selon une étude rétrospective sur 722 patients publiée dans les Annals of Oncology. Par Zosia Chustecka, Aude Lecrubier. Sur Medscape France http://www.medscape.fr/oncologie/articles/1494565/ USA: recul de la mortalité due au cancer Le recul de la mortalité due au cancer aux Etats-Unis, amorcé au début des années 1990, se poursuit avec une baisse de 1,8% par an de 2000 à 2009 chez les hommes et de 1,4% chez les femmes, selon le dernier rapport annuel fédéral publié aujourd’hui. Chez les enfants jusqu'à l'âge de 14 ans, le taux de décès dû au cancer a chuté de 1,8% par an. Dans Le Figaro http://www.lefigaro.fr/flash-actu/2013/01/07/97001-20130107FILWWW00645-usa-recul-de-la-mortalite-due-au-cancer.php Document de base (en anglais) : http://www.cancer.gov/ncicancerbulletin/010813/page5 CANCER, VIH: Booster le système immunitaire via des cellules souches tueuses Ces 2 recherches japonaises, publiées dans l’édition du 2 janvier de la revue Cell Stem Cell décrivent l’utilisation de cellules souches pour cloner et fabriquer de grandes quantités de globules blancs qui, produits par le système immunitaire sont capables de reconnaître des marqueurs spécifiques de cellules tumorales ou de VIH et d’attaquer ensuite puis tuer les cellules tumorales ou infectées. Dans Santé Log http://www.santelog.com/news/recherche-medicale/cancer-vih-booster-le-systeme-immunitaire-via-des-cellules-souches-tueuses_9674.htm Cancer Blog – Marc Lacroix – Le Blogue du Cancer http://marclacroixcancerblog.blogspot.com Marc Lacroix-Corman – InTextoResearch – Baelen (01/2013)
Technical Details
Message-ID:
<1390fd8c-0b7b-47ba-aa7c-a66b53bd7c78@hf3g2000vbb.googlegroups.com>Path:
arc1-ca.pugleaf.net!k2ni225qap.0!nntp.google.com!p13no1271997qai.0!postnews.google.com!hf3g2000vbb.googlegroups.com!not-for-mailShow Full Headers
Complete Article Headers
X-Google-Thread: a254ea4a8d,b6dfc47083fa6b47,start
X-Google-Attributes: gida254ea4a8d,public,usenet
X-Google-NewGroupId: yes
X-Google-Language: ENGLISH,CP1252
X-Received: by 10.224.189.78 with SMTP id dd14mr13290058qab.0.1357995554332;
Sat, 12 Jan 2013 04:59:14 -0800 (PST)
MIME-Version: 1.0
Received: by 10.49.15.100 with SMTP id w4mr14623683qec.26.1357995554261; Sat,
12 Jan 2013 04:59:14 -0800 (PST)
Path: arc1-ca.pugleaf.net!k2ni225qap.0!nntp.google.com!p13no1271997qai.0!postnews.google.com!hf3g2000vbb.googlegroups.com!not-for-mail
Newsgroups: be.science
Date: Sat, 12 Jan 2013 04:59:14 -0800 (PST)
Complaints-To: groups-abuse@google.com
Injection-Info: hf3g2000vbb.googlegroups.com; posting-host=81.247.138.39; posting-account=jR3pwAkAAABfF7uqn-zMzWqez-yhPWKE
NNTP-Posting-Host: 81.247.138.39
User-Agent: G2/1.0
X-HTTP-UserAgent: Mozilla/5.0 (Windows NT 5.1) AppleWebKit/537.11 (KHTML, like
Gecko) Chrome/23.0.1271.97 Safari/537.11,gzip(gfe)
Message-ID: <1390fd8c-0b7b-47ba-aa7c-a66b53bd7c78@hf3g2000vbb.googlegroups.com>
Subject: Cancer - Press Review (January 12, 2013) – Revue de presse (12 janvier 2013)
From: SMW <scimedweb@mail.com>
Injection-Date: Sat, 12 Jan 2013 12:59:14 +0000
Content-Type: text/plain; charset=windows-1252
Content-Transfer-Encoding: quoted-printable